Cat. No.: HY-108543

NSC 95397

9 Cited Publications

Customer Review

Based on 9 publication(s) in Google Scholar

NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC₅₀=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)). NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway.

For research use only. We do not sell to patients.

Purity: 99.0%
CAS No.: 93718-83-3
Formula: C₁₄H₁₄O₄S₂
Molecular Weight:310.39

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

NSC 95397 Chemical Structure

CAS No.: 93718-83-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (9)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC₅₀=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B))^[1]. NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway^[2].

IC₅₀ & Target

Ki: 32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C)^[1]
IC50: 22.3 nM (human Cdc25A) , 56.9 nM (human Cdc25C), 125 nM (Cdc25B)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	1.45 μM Compound: NCS 95397	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
A549	IC₅₀	13.1 μM Compound: 4; NSC 95397	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
HeLa	IC₅₀	10.8 μM Compound: NSC-95397	Cytotoxicity against human HeLa cells after 6 days by WST1 colorimetric assay Cytotoxicity against human HeLa cells after 6 days by WST1 colorimetric assay	[PMID: 18789703]
HeLa	IC₅₀	8.5 μM Compound: NSC-95397	Antiproliferative activity against human HeLa cells after 10 days by clonogenic assay Antiproliferative activity against human HeLa cells after 10 days by clonogenic assay	[PMID: 18789703]
HL-60	IC₅₀	1 μM Compound: 4; NSC 95397	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
Hs 683	IC₅₀	2.8 μM Compound: NCS 95397	Cytotoxicity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
Jurkat	IC₅₀	3.7 μM Compound: 4; NSC 95397	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
LS174T	IC₅₀	18.1 μM Compound: 4; NSC 95397	Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MCF7	IC₅₀	0.96 μM Compound: NCS 95397	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
MCF7	IC₅₀	9.4 μM Compound: 4; NSC 95397	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MONO-MAC-6	IC₅₀	4.2 μM Compound: 4; NSC 95397	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PBMC	IC₅₀	7.8 μM Compound: 4; NSC 95397	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PC-3	IC₅₀	3.4 μM Compound: NCS 95397	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
SK-MEL-28	IC₅₀	2.3 μM Compound: NCS 95397	Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28431339]
SW982	IC₅₀	7.9 μM Compound: 4; NSC 95397	Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
THP-1	IC₅₀	1.4 μM Compound: 4; NSC 95397	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
U-937	IC₅₀	3.9 μM Compound: 4; NSC 95397	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]

In Vitro

NSC 95397 (0, 10, and 20 μM; 24 hour) decreases the cell viability of three colon cancer cell lines SW480, SW620, and DLD-1 in a concentration-dependent manner^[2].
? NSC 95397(10 μM; 24 hour) upregulates p21 while downregulates CDK4 and CDK6 were d in all three colon cancer cell lines SW480, SW620, and DLD-1 cells^[2].
? NSC 95397 (10 μM;? 24 hour) reduces the phosphorylation of retinoblastoma protein (Rb) on Ser795 and Ser807/811^[2].
? NSC 95397 (20 μM; 24 hours) significantly increases cleaved caspase-9, -3, -7 and PARP levels^[2].
? NSC 95397 (10 μM; 6 hours) enhances the phosphorylation of its downstream ERK1/2 at Thr202/Tyr 204^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Human colon cancer cell lines, SW480, SW620, and DLD-1
Concentration:

0, 10, and 20 µM
Incubation Time:

24 hours
Result:

The IC₅₀ values of NSC 95397 for the cell growth of SW480, SW620, and DLD-1 cells were 9.9, 14.1 and 18.6 μM, respectively.

Western Blot Analysis^[2]

Cell Line:

SW480, SW620, and DLD-1 cells
Concentration:

10 μM
Incubation Time:

24 hours
Result:

p21 was upregulated while CDK4 and CDK6 were downregulated.
Rduced the phosphorylation of Rb on Ser795 and Ser807/811

Chemical Information

CAS No. 93718-83-3
Appearance Solid
Molecular Weight 310.39
Formula C₁₄H₁₄O₄S₂
Color Light yellow to orange
SMILES

O=C1C(SCCO)=C(SCCO)C(C2=C1C=CC=C2)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (9)

All

Sort by:

Journal Impact Factor

J Neuroinflammation

Melanin concentrating hormone regulates the JNK/ERK signaling pathway to alleviate influenza A virus infection-induced neuroinflammation. [Abstract]

2024 Oct 10;21(1):259. PMID: 39390522
Phytomedicine

Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1/NF-κB pathway. [Abstract]

2021 Nov;92:153743. PMID: 34583225
Cell Biol Toxicol

CtBP1-LSD1 complex drives ErbB2 activation via H3K9me2 demethylation in DRGs during paclitaxel-induced neuropathic pain. [Abstract]

2025 Dec 18;42(1):1. PMID: 41410814
Biol Direct

PNSC928, a plant-derived compound, specifically disrupts CtBP2-p300 interaction and reduces inflammation in mice with acute respiratory distress syndrome. [Abstract]

2024 Jun 21;19(1):48. PMID: 38902802
J Cancer Res Clin Oncol

KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway. [Abstract]

2024 May 7;150(5):239. PMID: 38713252
Biochem Biophys Res Commun

Inhibition of CDC25C attenuates IL-17A-driven keratinocyte hyperproliferation and psoriasis progression. [Abstract]

2026 Feb 26:802:153342. PMID: 41587503
Cell Physiol Biochem

Stimulation of Suicidal Erythrocyte Death by the CDC25 Inhibitor NSC-95397. [Abstract]

2016;40(3-4):597-607. PMID: 27889774
bioRxiv

2024 Feb 5.
Bioengineered

CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma. [Abstract]

2022 May;13(5):13089-13107. PMID: 35615982

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (322.18 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2218 mL

16.1088 mL

32.2175 mL

5 mM

0.6444 mL

3.2218 mL

6.4435 mL

10 mM

0.3222 mL

1.6109 mL

3.2218 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 10 mg/mL (32.22 mM); Clear solution

This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 10 mg/mL (32.22 mM); Clear solution

This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lazo JS, et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol. 2002 Apr;61(4):720-8. [Content Brief]

[2]. Dubey NK, et al. NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway. Int J Mol Sci. 2018 May 31;19(6). pii: E1625. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2218 mL	16.1088 mL	32.2175 mL	80.5438 mL
	5 mM	0.6444 mL	3.2218 mL	6.4435 mL	16.1088 mL
	10 mM	0.3222 mL	1.6109 mL	3.2218 mL	8.0544 mL
	15 mM	0.2148 mL	1.0739 mL	2.1478 mL	5.3696 mL
	20 mM	0.1611 mL	0.8054 mL	1.6109 mL	4.0272 mL
	25 mM	0.1289 mL	0.6444 mL	1.2887 mL	3.2218 mL
	30 mM	0.1074 mL	0.5370 mL	1.0739 mL	2.6848 mL
	40 mM	0.0805 mL	0.4027 mL	0.8054 mL	2.0136 mL
	50 mM	0.0644 mL	0.3222 mL	0.6444 mL	1.6109 mL
	60 mM	0.0537 mL	0.2685 mL	0.5370 mL	1.3424 mL
	80 mM	0.0403 mL	0.2014 mL	0.4027 mL	1.0068 mL
	100 mM	0.0322 mL	0.1611 mL	0.3222 mL	0.8054 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

NSC 95397

Apoptosis Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Phosphatase Inhibitor Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) NSC 95397

Biological Activity

Chemical Information

Publications (9)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

NSC 95397

Apoptosis Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Phosphatase Inhibitor Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) NSC 95397

Biological Activity

Chemical Information

Publications (9)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

NSC 95397 Related Classifications

HY-108543 Related Classifications